
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics Inc is advancing its pipeline candidates in high-value indications, notably highlighting the potential impact of SER-270 and its implications for long-term forecasts. The company's valuation assessment currently does not account for contributions from SER-270 or other pipeline candidates beyond SER-252, suggesting that successful clinical developments in these areas could significantly enhance the company's financial outlook. Additionally, the broadening approval trajectory of enFuse is anticipated to positively influence the global acceptance of SER-252, further solidifying the investment case for Serina Therapeutics.
Bears say
Serina Therapeutics has reported a consistent net loss of $0.64 per share, highlighting ongoing financial challenges that may reflect deeper operational issues within the company. The company faces multiple risks that could hinder the advancement of its lead candidate, SER-252, including delays in clinical assessment, difficulties in securing regulatory approvals, and slower-than-anticipated commercial uptake due to increased competition and market dynamics. Furthermore, revised forecasts indicate a significant increase in projected net losses, with estimates for 2025 rising dramatically to a loss of $2.01 per share, suggesting concerns over financial sustainability and future performance.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares